You are here:

daclizumab (Zinbryta)

Advice

following a full submission:

daclizumab (Zinbryta®)  is accepted for restricted use within NHS Scotland.

Indication under review: In adult patients for the treatment of relapsing forms of multiple sclerosis.

Restriction: for use 
• in patients with rapidly evolving severe (RES) relapsing remitting multiple sclerosis (RRMS) or
• in patients with RRMS with an inadequate response to disease modifying therapy

In a phase III study, the adjusted annualised relapse rate (over a period of 144 weeks) was statistically significantly lower for daclizumab than for an interferon beta treatment in patients with RRMS.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of daclizumab. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.

Drug Details

Drug Name: daclizumab (Zinbryta)
SMC Drug ID: 1216/17
Manufacturer: Biogen Idec Ltd
Indication: In adult patients for the treatment of relapsing forms of multiple sclerosis.
BNF Category:
Sub Category: 8.2 Drugs affecting the immune response
Submission Type: Full submission
Status: Restricted
Date Advice Published: 10 April 2017

Back